Monoamine Oxidase Inhibitors

• 

  Subject Areas on Research

  • A history of the concept of atypical depression. 
  • A history of the concept of atypical depression. 
  • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. 
  • A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. 
  • Acetylenics. 2. Synthesis and pharmacology of certain N,N-diakyl-3-phenylpropyn-2-amines. Some analogues with tryptamine-like behavioral effects in mice. 
  • Adding a tricyclic antidepressant to a monoamine oxidase inhibitor. 
  • Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. 
  • Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial. 
  • Atypical depression. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Catecholamine release and uptake in the mouse prefrontal cortex. 
  • Cerebral amino acid, norepinephrine and nitric oxide metabolism in CNS oxygen toxicity. 
  • Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Defining an appropriate management strategy for social anxiety disorder. 
  • Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats. 
  • Does dopamine contribute to striatal damage caused by impaired mitochondrial function? 
  • Efficacy of newer medications for treating depression in primary care patients. 
  • Forms of atypical depression and their response to antidepressant drugs. 
  • Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. 
  • International advances in the treatment of social phobia. 
  • MAO inhibition and control of anxiety following amitriptyline therapy. A pilot study. 
  • Moclobemide in social phobia: a controlled dose-response trial. 
  • Monoamine oxidase inhibitors in patients with chronic pain. 
  • Neuroticism and personality disorder in depression. 
  • Patient compliance with MAO inhibitor therapy. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pharmacotherapy of social phobia. 
  • Platelet MAO inhibition following tricyclic antidepressant therapy. 
  • Practical aspects of MAO inhibitor therapy. 
  • Predictors of response to monoamine oxidase inhibitors: do they exist? 
  • Predictors of treatment response in patients with posttraumatic stress disorder. 
  • Prevention of H2O2 generation by monoamine oxidase protects against CNS O2 toxicity. 
  • Quantitative measurement of postural sway in mouse models of human neurodegenerative disease. 
  • Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela. 
  • Relapse, side effects, and monoamine oxidase inhibition during long term use of isocarboxazid: a case report. 
  • Revisiting monoamine oxidase inhibitors. 
  • Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. 
  • Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social phobia: issues in assessment and management. 
  • The Newcastle Anxiety Depression Diagnostic Index in relationship to the effects of monoamine oxidase inhibitors and tricyclic antidepressants. 
  • Tribulin in post-traumatic stress disorder. 
  • Urinary metabolities of harmine in the rat and their inhibition of monoamine oxidase. 
  • trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.